Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Korea Stock Exchange  >  NH Investment & Securities Co., Ltd.    A005940   KR7005940002

NH INVESTMENT & SECURITIES CO., LTD.

(A005940)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Vaccine developer SK Bioscience targets IPO in first half of 2021

11/27/2020 | 03:37am EST

SEOUL (Reuters) - South Korean drug company SK Bioscience aims to seek a domestic stock market listing in the first half of next year, it said on Friday.

The plan follows successful initial public offerings (IPOs) by its affiliate SK Biopharmaceuticals and other companies, such as Kakao Games, which attracted huge interest from Korean retail investors seeking higher returns in the face of near-zero interest rates.

SK Bioscience, which is 98% owned by SK Chemical, said its board has approved the potential IPO and it has hired NH Investment & Securities as lead manager.

The company said the share sale will enable it to respond to the rapidly changing environment, such as the spread of COVID-19, and enhance shareholder value through continued investment and technological innovation.

SK Bioscience this week received regulatory approval to begin human clinical trials of its COVID-19 experimental vaccine, having agreed in July to manufacture AstraZeneca's experimental vaccine to help the British company build global supplies.

The agreement was followed by another deal to manufacture a component of U.S. drug developer Novavax Inc's experimental COVID-19 vaccine.

(Reporting by Sangmi Cha and Hyunjoo Jin; Editing by Shri Navaratnam and David Goodman)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 1.45% 7678 Delayed Quote.4.62%
NH INVESTMENT & SECURITIES CO., LTD. -2.98% 11400 End-of-day quote.0.88%
NOVAVAX, INC. -1.96% 127.43 Delayed Quote.14.28%
SK BIOPHARMACEUTICALS CO., LTD. -3.27% 148000 End-of-day quote.-12.43%
SK CHEMICALS CO.,LTD. 7.58% 376000 End-of-day quote.-4.20%
All news about NH INVESTMENT & SECURITIES CO., LTD.
2020MARKET CHATTER : NH Investment and Maeil Business Launch New ESG Index
MT
2020Vaccine developer SK Bioscience targets IPO in first half of 2021
RE
2020Lee's death sparks hope for Samsung shake-up, dividends
RE
2020NH INVESTMENT & SECURITIES : ADNOC inks $10 billion deal, keeps tight control of..
RE
2020K-POP SENSATION BTS' LABEL PICKS JPM : media
RE
2018South Korea's Hyundai Mobis to meet Elliott next week - sources
RE
2015Global banks extend retreat from Asian bond markets - researcher
RE
2014Heirs of Samsung's Lee don't plan to sell shares in holding firm IPO
RE
2014POSCO to revamp non-steel ops, shun major steel investment -new CEO
RE
2014POSCO believes Indonesia mill unlikely to make profit this year
RE
More news
Financials
Sales 2020 1 781 B 1,62 B 1,62 B
Net income 2020 624 B 0,57 B 0,57 B
Net Debt 2020 - - -
P/E ratio 2020 5,33x
Yield 2020 5,10%
Capitalization 3 357 B 3 039 M 3 048 M
Capi. / Sales 2020 1 884x
Capi. / Sales 2021 1 939x
Nbr of Employees 2 971
Free-Float 44,4%
Chart NH INVESTMENT & SECURITIES CO., LTD.
Duration : Period :
NH Investment & Securities Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NH INVESTMENT & SECURITIES CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 13 472,73 KRW
Last Close Price 11 400,00 KRW
Spread / Highest target 38,6%
Spread / Average Target 18,2%
Spread / Lowest Target -3,51%
EPS Revisions
Managers and Directors
NameTitle
Young-Chae Jeong President, Chief Executive Officer & Director
Young-Kyun Na Managing Director & Head-Operation
Yong-Seok Jeon Managing Director & Head-Information Technology
Jung-Dae Lee Non-Executive Director
Hong-Yul Jeon Independent Director